A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Phase 2
250
about 2.2 years
18+
7 sites in AK, FL, LA +3
About this study
This trial is testing if MK-5684, a treatment for cancer, can help people with breast, ovarian, and endometrial cancers live longer without their cancer growing or spreading. Researchers will compare MK-5684 to standard treatments used for these types of cancers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dexamethasone/Dexamethasone acetate
- 2.Take Exemestane
- 3.Take Fludrocortisone/ Fludrocortisone acetate
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
dexamethasone, Anti-inflammatory Agent (Corticosteroid Hormone Receptor Agonists), exemestane, fludrocortisone, Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) (Mineralocorticoid Receptor Agonists), fulvestrant, letrozole (Aromatase inhibitor; prevents estrogen production), Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) (Progestational Hormone Receptor Agonists)
injection, ocular, oral, oral (Oral Tablet), intramuscular
Primary: Progression-Free Survival (PFS) - All Cohorts
Secondary: Duration of Response (DOR) - All Cohorts, Number of Participants who Discontinue Study Intervention Due to an Adverse Event (AE) - All Cohorts, Number of Participants who Experience One or More Adverse Events (AEs) - All Cohorts, Objective Response Rate (ORR) - All Cohorts, Overall Survival (OS) - All Cohorts
Oncology